Characterization of a cannabinoid CB2 receptor-selective agonist, A-836339 [2,2,3,3-tetramethyl-cyclopropanecarboxylic acid [3-(2-methoxy-ethyl)-4,5-dimethyl-3H-thiazol-(2Z)-ylidene]-amide], using in vitro pharmacological assays, in vivo pain models

Characterization of a cannabinoid CB2 receptor-selective agonist, A-836339 [2,2,3,3-tetramethyl-cyclopropanecarboxylic acid [3-(2-methoxy-ethyl)-4,5-dimethyl-3H-thiazol-(2Z)-ylidene]-amide], using in vitro pharmacological assays, in vivo pain models

Item

http://www.wikidata.org/entity/Q34860053

Q34860053

about

Antinociceptive effects of racemic AM1241 and its chirally synthesized enantiomers: lack of dependence upon opioid receptor activation.Synthesis and biodistribution of [11C]A-836339, a new potential radioligand for PET imaging of cannabinoid type 2 receptors (CB2).Cannabinoids as pharmacotherapies for neuropathic pain: from the bench to the bedside CB2: a cannabinoid receptor with an identity crisis Chronic cannabinoid receptor 2 activation reverses paclitaxel neuropathy without tolerance or cannabinoid receptor 1-dependent withdrawal The CB2 cannabinoid receptor-selective agonist O-3223 reduces pain and inflammation without apparent cannabinoid behavioral effects.Heteromerization of GPR55 and cannabinoid CB2 receptors modulates signalling Tolerance to chronic delta-9-tetrahydrocannabinol (Δ⁹-THC) in rhesus macaques infected with simian immunodeficiency virus CB1 and CB2 receptor agonists promote analgesia through synergy in a murine model of tumor pain Cannabinoid CB2 Receptors in a Mouse Model of Aβ Amyloidosis: Immunohistochemical Analysis and Suitability as a PET Biomarker of Neuroinflammation 2,3-Dihydro-1-benzofuran derivatives as a series of potent selective cannabinoid receptor 2 agonists: design, synthesis, and binding mode prediction through ligand-steered modeling.Functional selectivity in CB(2) cannabinoid receptor signaling and regulation: implications for the therapeutic potential of CB(2) ligands.CB1 Knockout Mice Unveil Sustained CB2-Mediated Antiallodynic Effects of the Mixed CB1/CB2 Agonist CP55,940 in a Mouse Model of Paclitaxel-Induced Neuropathic Pain.Latest advances in cannabinoid receptor agonists.Dynamic changes to the endocannabinoid system in models of chronic pain.Novel thiazole derivatives: a patent review (2008 - 2012. Part 2).Modulating the delicate glial-neuronal interactions in neuropathic pain: promises and potential caveats.Cannabinoids in pain management: CB1, CB2 and non-classic receptor ligands.The Endogenous Cannabinoid System: A Budding Source of Targets for Treating Inflammatory and Neuropathic Pain.Combination Chemistry: Structure-Activity Relationships of Novel Psychoactive Cannabinoids.Immunofluorescent spectral analysis reveals the intrathecal cannabinoid agonist, AM1241, produces spinal anti-inflammatory cytokine responses in neuropathic rats exhibiting relief from allodynia.The Central Role of Glia in Pathological Pain and the Potential of Targeting the Cannabinoid 2 Receptor for Pain Relief.Evaluation of first generation synthetic cannabinoids on binding at non-cannabinoid receptors and in a battery of in vivo assays in mice.Central and peripheral sites of action for CB₂ receptor mediated analgesic activity in chronic inflammatory and neuropathic pain models in rats Legal controls on cannabimimetics: an international dilemma?Radioligands for positron emission tomography imaging of cannabinoid type 2 receptor.Current evidence of cannabinoid-based analgesia obtained in preclinical and human experimental settings.Highly selective CB2 receptor agonist A836339 has gastroprotective effect on experimentally induced gastric ulcers in mice.

P2860

Q33749455-8CCCEE92-6F21-42B4-915F-4A572E75D85D Q33992517-F619E007-944B-4A2E-853A-14F943B55AE9 Q34019573-144D00A9-9DA3-4E3A-B31C-28EC01FBEC00 Q34098185-B3AE0E85-74A1-409B-BB87-876BD5B6F0B2 Q34403197-2CE39174-83FF-4BF1-9DFE-DC6332580C0A Q34496064-3E8FDAA0-A4C0-4255-AC7E-ED4C606DD01A Q34953430-45B49D1F-B5E0-4802-9EE0-DDA3CFA836BB Q35119113-42FEE431-01D0-4199-A95B-CA1ACAE6FA3C Q35162945-540A7929-DC6A-432E-908F-0754FDC7ECBF Q35667387-76F66531-16B5-4C8E-BE01-F445592EB4DD Q35685828-68E4267C-E235-4806-9CAC-4D83B392C516 Q35688511-76132091-DBEB-464D-B094-871E40CC4112 Q35745959-C334ED34-A385-4277-951C-58489AD90F41 Q37638736-8C73272B-6EEC-447E-A197-0F1DFF90D04D Q38056398-F62E9A44-D948-441E-9CA4-45DD9F226F7F Q38205485-D2E1CFD7-6B33-4E17-8AC7-77B6D0C49A74 Q38211273-9B647075-3D5C-4275-9D63-415EA2B43148 Q38212376-CDFDC980-B87D-430B-B430-610DE6C8CDA1 Q38600704-E1DBD3B3-5934-406F-99ED-81A196FC1A74 Q38983634-A8FD474E-A2AE-4C9C-B15F-A97C3BB525D4 Q39248070-4FF011C2-46B9-409B-8AC5-33188090126A Q39274311-8362965E-B420-4B00-80C5-14C4C71AFFB8 Q42581822-CC31DC33-4B37-4A5A-85D4-99A1CE81BE2C Q42585836-20642744-99BF-43A5-A135-39653F45A404 Q44229442-5F206831-B3CC-4F60-AA72-6B4E1ECF5B1F Q47432979-02B83F48-2FBE-485A-9FF1-D3AE29C45820 Q47958585-96CD4721-2D7E-42D6-814F-7B317792CE02 Q52762339-99594237-12B6-4711-A42C-BA8569989156

P2860

Characterization of a cannabinoid CB2 receptor-selective agonist, A-836339 [2,2,3,3-tetramethyl-cyclopropanecarboxylic acid [3-(2-methoxy-ethyl)-4,5-dimethyl-3H-thiazol-(2Z)-ylidene]-amide], using in vitro pharmacological assays, in vivo pain models

Item

http://www.wikidata.org/entity/Q34860053

description

2008 nî lūn-bûn

@nan

2008 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue